Compare · APO vs HQL
APO vs HQL
Side-by-side comparison of Apollo Global Management Inc. (New) (APO) and abrdn Life Sciences Investors Shares of Beneficial Interest (HQL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APO and HQL operate in Investment Managers (Finance), so they compete in similar markets.
- APO is the larger of the two at $73.55B, about 171.8x HQL ($428.1M).
- Over the past year, APO is down 4.4% and HQL is up 29.8% - HQL leads by 34.2 points.
- APO has been more active in the news (5 items in the past 4 weeks vs 2 for HQL).
- APO has more recent analyst coverage (25 ratings vs 0 for HQL).
- Company
- Apollo Global Management Inc. (New)
- abrdn Life Sciences Investors Shares of Beneficial Interest
- Price
- $127.60-0.34%
- $16.65-1.39%
- Market cap
- $73.55B
- $428.1M
- 1M return
- -0.13%
- -7.24%
- 1Y return
- -4.45%
- +29.77%
- Industry
- Investment Managers
- Investment Managers
- Exchange
- NYSE
- NYSE
- IPO
- 1992
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 0
Apollo Global Management Inc. (New)
Apollo Global Management, Inc. is a private equity firm specializing investments in credit, private equity and real estate markets. The firm's private equity investments include traditional buyouts, recapitalization, distressed buyouts and debt investments in real estate, corporate partner buyouts, distressed asset, corporate carve-outs, middle market, growth capital, turnaround, bridge, corporate restructuring, special situation, acquisition, and industry consolidation transactions. The firm provides its services to endowment and sovereign wealth funds, as well as other institutional and individual investors. It manages client focused portfolios. The firm launches and manages hedge funds for its clients. It also manages real estate funds and private equity funds for its clients. The firm invests in the fixed income and alternative investment markets across the globe. Its fixed income investments include income-oriented senior loans, bonds, collateralized loan obligations, structured credit, opportunistic credit, non-performing loans, distressed debt, mezzanine debt, and value oriented fixed income securities. The firm seeks to invest in chemicals, commodities, consumer and retail, oil and gas, metals, mining, agriculture, commodities, distribution and transportation, financial and business services, manufacturing and industrial, media distribution, cable, entertainment and leisure, telecom, technology, natural resources, energy, packaging and materials, and satellite and wireless industries. It seeks to invest in companies based in across North America with a focus on United States, and Europe. The firm also makes investments outside North America, primarily in Western Europe and Asia. It employs a combination of contrarian, value, and distressed strategies to make its investments. The firm seeks to make investments in the range of $10 million and $1.5 billion. The firm seeks to invest in companies with Enterprise value between $200 million to $2.5 billion. The firm conducts an in-house research to create its investment portfolio. It seeks to acquire minority and majority positions in its portfolio companies. The firm was formally know as Apollo Global Management, LLC. Apollo Global Management, Inc. was founded in 1990 and is headquartered in New York, New York with additional offices in North America, Asia and Europe
abrdn Life Sciences Investors Shares of Beneficial Interest
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Latest APO
- Apollo Funds Complete Sale of ALTEMIRA, Leading Pan-Asian Aluminum Packaging Company
- Bridge Logistics Properties Raises Nearly $1.4 Billion For Its Value Fund II, Exceeding $1 Billion Target
- Apollo to Present at the Morgan Stanley 2026 US Financials Conference
- Athene Announces Key Leadership Appointment
- Apollo to Present at the Bernstein 42nd Annual Strategic Decisions Conference
- Stream Data Centers' Executive Leadership Expands to Meet Accelerated Hyperscale Demand, Deliver Efficient, Capital-Backed Results
- Apollo Funds Acquire Majority Stake in Noble Environmental, Inc.
- MidOcean Partners Signs Definitive Agreement to Exit Questex
- Onex Partners Announces the Sale of Emerald to Apollo Funds
- Apollo Funds to Acquire Emerald and Questex to Create Leading North American B2B Events Platform
Latest HQL
- SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- SEC Form 3 filed by new insider Reilly Heather Carter
- Director Pittard Christian bought $133,755 worth of shares (7,923 units at $16.88) (SEC Form 4)
- SEC Form N-CSR filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- SEC Form N-CEN filed by abrdn Life Sciences Investors Shares of Beneficial Interest